BRAF and melanoma: Trametinib is already approved for the treatment of BRAF-mutated melanoma and lung cancer in combination with Dabrafenib33,34, and Lestaurtinib, a staurosporine derivative, completed a phase III clinical trial for the treatment of acute myeloid leukemia (AML)35.